B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA) - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Frontiers in Oncology Année : 2022

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Maria Stefania Infante (1) , Jon Salmanton-García (2, 3) , Ana Fernández-Cruz (4) , Francesco Marchesi (5) , Ozren Jaksic (6) , Barbora Weinbergerová (7) , Caroline Besson (8) , Rafael F Duarte (4) , Federico Itri (9) , Toni Valković (10, 11) , Tomáš Szotkovski (12) , Alessandro Busca (13) , Anna Guidetti (14) , Andreas Glenthøj (15) , Graham P Collins (16) , Valentina Bonuomo (17) , Uluhan Sili (18) , Guldane Cengiz Seval (19) , Marina Machado (20) , Raul Cordoba (21) , Ola Blennow (18) , Ghaith Abu-Zeinah (22) , Sylvain Lamure , Sylvain Lamure (23, 24) , Austin Kulasekararaj (25) , Iker Falces-Romero (26) , Chiara Cattaneo (27) , Jaap van Doesum (28) , Klára Piukovics (29) , Ali S Omrani (30) , Gabriele Magliano (31) , Marie-Pierre Ledoux (32) , Cristina de Ramon (33, 34) , Alba Cabirta (35, 36) , Luisa Verga (37, 38) , Alberto López-García (21) , Maria Gomes da Silva (39) , Zlate Stojanoski (40) , Stef Meers (41) , Tobias Lahmer (42) , Sonia Martín-Pérez (43) , Julio Dávila-Vals (43) , Jens van Praet (44) , Michail Samarkos (45) , Yavuz M Bilgin (46) , Linda Katharina Karlsson (15) , Josip Batinić (47) , Anna Nordlander (18) , Martin Schönlein (48) , Martin Hoenigl (49, 50, 51) , Zdeněk Ráčil (52) , Miloš Mladenović (53) , Michaela Hanakova (52) , Giovanni Paolo Maria Zambrotta (54, 38) , Nick de Jonge (55) , Tatjana Adžić-Vukičević (53) , Raquel Nunes-Rodrigues (39) , Lucia Prezioso (56) , Milan Navrátil (57) , Monia Marchetti (58) , Annarosa Cuccaro (59) , Maria Calbacho (60) , Antonio Giordano (61, 62) , Oliver A Cornely (2, 63, 64, 65, 66) , José-Ángel Hernández-Rivas (1) , Livio Pagano (62)
1 Hospital Universitario Infanta Leonor [Madrid]
2 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD)
3 University of Cologne
4 Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain]
5 IRE - IFO - Istituto Nazionale Tumori Regina Elena [Roma]
6 Dubrava University Hospital
7 MUNI - Masaryk University [Brno]
8 CHV - Centre Hospitalier de Versailles André Mignot
9 SLGUH Orbassano - San Luigi Gonzaga University Hospital [Turin, Italy]
10 University Hospital Rijeka
11 CROHEM - Croatian Cooperative Group for Hematological Diseases
12 University Hospital Olomouc
13 AOU Città della Salute e della Scienza Hospital
14 IRCCS Istituto Nazionale dei Tumori [Milano]
15 Rigshospitalet [Copenhagen]
16 Churchill Hospital Oxford Centre for Haematology
17 UNIVR - Università degli studi di Verona = University of Verona
18 Marmara University [Kadıköy - İstanbul]
19 Ankara University School of Medicine [Turkey]
20 Hospital General Universitario "Gregorio Marañón" [Madrid]
21 Fundación Jiménez Díaz
22 Weill Cornell Medicine [Cornell University]
23 CHU Montpellier
24 IGMM - Institut de Génétique Moléculaire de Montpellier
25 KCH - King's College Hospital
26 La Paz University Hospital
27 ASST Spedali Civili of Brescia,
28 UMCG - University Medical Center Groningen [Groningen]
29 University of Szeged [Szeged]
30 Hamad Medical Corporation [Doha, Qatar]
31 ASST Great Metropolitan Niguarda / ASST Grande Ospedale Metropolitano Niguarda [Milan, Italia]
32 ICANS - Institut de Cancérologie de Strasbourg Europe
33 Hospital Universitario de Salamanca
34 IBSAL/CIC - Instituto de Investigación Biomédica de Salamanca [Salamanca, Spain]
35 VHIO - Vall d'Hebron Institute of Oncology [Barcelone]
36 UAB - Universitat Autònoma de Barcelona
37 Azienda Ospedaliera San Gerardo
38 UNIMIB - Università degli Studi di Milano-Bicocca = University of Milano-Bicocca
39 IPO Porto - Instituto Português de Oncologia do Porto / Portuguese Oncology Institute of Porto
40 UCH - University Clinic of Hematology [Skopje, Republic of North Macedonia]
41 AZ Klina
42 MRI TUM - Klinikum rechts der Isar
43 Hospital Nuestra Señora de Sonsoles
44 Department of ENT surgery, AZ Sint Jan Brugge Oostende
45 Laikon General Hospital
46 ADRZ - Admiral de Ruyter Medical Center
47 University Hospital Centre Zagreb
48 UKE - Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg]
49 UC San Diego Health
50 La Jolla Institute for Immunology [La Jolla, CA, États-Unis]
51 Medical University of Graz
52 Institute of Hematology and Blood Transfusion [Prague, Czech Republic]
53 COVID Hospital "Batajnica" (Belgrade)
54 SGH - San Gerardo Hospital [Monza, Italy]
55 Amsterdam UMC - Amsterdam University Medical Centers
56 UO Ematologia/CTMO
57 University Hospital Ostrava
58 Ospedale SS Antonio e Biagio e Cesare Arrigo
59 AUTNO - Azienda Usl Toscana nord ovest [Livorno, Italy]
60 Hospital Universitario 12 de Octubre [Madrid]
61 Fondazione Policlinico Universitario Agostino Gemelli IRCCS
62 Unicatt - Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma]
63 University Hospital of Cologne [Cologne]
64 ZKS - Centre for Clinical Studies
65 CMMC - Center for Molecular Medicine [Cologne]
66 DZIF - German Center for Infection Research - Partner Site Bonn-Cologne
Sylvain Lamure
  • Fonction : Auteur
Stef Meers
  • Fonction : Auteur

Résumé

Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
Fichier principal
Vignette du fichier
fonc-12-992137 (1).pdf (2.59 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY - Paternité

Dates et versions

hal-04427149 , version 1 (30-01-2024)

Licence

Paternité

Identifiants

Citer

Maria Stefania Infante, Jon Salmanton-García, Ana Fernández-Cruz, Francesco Marchesi, Ozren Jaksic, et al.. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA). Frontiers in Oncology, 2022, 12, ⟨10.3389/fonc.2022.992137⟩. ⟨hal-04427149⟩
2 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More